Associate Professor Colin Dunstan

BSc Sydney, MSc UNSW, PhD Sydney
Associate Professor
School of Aerospace, Mechanical and Mechatronic Engineering

Telephone +61 2 9351 7127
Fax +61 2 9351 7060

Website School of Aerospace, Mechanical and Mechatronic Engineering

Biomechanics, Biomaterials and Tissue Engineering

ANZAC Research Institute

Curriculum vitae Curriculum vitae

Map

Biographical details

Associate Professor Colin Dunstan is a respected authority on bone metabolism with over 25 years of experience in both clinical and basic research. He was part of the team that identified osteoprotegerin, RANK ligand and RANK as central regulators of bone resorption. He has extensive experience in both academic and industry (Amgen) settings. He currently serves on the editorial boards of Endocrinology and the Journal of Bone and Mineral Research. Current research interests are in the local regulation of bone remodelling and in interactions between bone cell activity and cancer cells.

Research interests

Bone is a living tissue, whose strength is dependent on the actions and interactions of its cells. Associate Professor Colin Dunstan's research seeks to understand these better, and to identify the processes leading to bone damage and repair. In this way he is contributing to the development of improved interventions to prevent and treat bone damage due to cancer, osteoporosis and other disorders.

"Bone cells can detect bone damage and strain, remove damaged or aged bone, and strengthen and repair bone, enabling it to resist fracture and provide the support and protection needed by the soft tissues of the body.

"The function of these bone cells is dependent on complex signalling between bone cells and the bone itself. Many diseases - including osteoporosis, inflammatory diseases and cancer - disrupt these signalling pathways, weakening bones and leading to fractures.

"My commitment to this field has been driven by the opportunity to use my research findings to produce significant improvements in patient care.

"The impacts of my research so far have included identifying the high prevalence of aluminium accumulation in the bone of dialysis patients, leading to improved dialysis protocols, and developing a drug that offers the best currently available prevention of skeletal complications in advanced cancer and has worldwide annual sales of more than $1 billion.

"Currently I am working to develop new biomaterials to repair bone defects without requiring painful harvesting of bone from other sites in the patient's body. I am also seeking to understand how to prevent the spread of prostate and breast cancer cells to bone by changing the bone microenvironment.

"My overall goal is to collaborate with industry to enable the efficient translation of research discoveries into products that benefit patients and build commercial achievements in Australia.

"I have been working in this field since graduating from the University of Sydney in 1977. Working here has provided me with wonderful resources for research and great opportunities for collaboration."

Teaching and supervision

AMME4990 - Biomedical Product Development

AMME5022 - Capstone Project B Extended

AMME5901 - Anatomy and Physiology for Engineers

AMME5990 - Biomedical Engineering Technology 1

ENGG1960 - Introduction to Biomedical Engineering

MECH2901 - Anatomy and Physiology for Engineers

MECH3661 - Engineering Management

Themes

Cancer; Biomedical engineering and technology; Healthy Ageing

Selected grants

2015

  • The SurPASS Electrokinetic Surface Potential Analyser for Solid Samples; Dunstan C, Jabbarzadeh A, Neto C, Zreiqat H, Murray M; DVC Research/Equipment Grant.
  • Development of novel anti-cancer agents based on cytochrome P450-mediated epoxides of omega-3 fatty acids; Murray M, Dunstan C, Rawling T; National Health and Medical Research Council (NHMRC)/Project Grants.

2014

  • Engineering strategies for bone regeneration through microstructural design; Zreiqat H, Dunstan C; Rebecca L Cooper Medical Research Foundation/Equipment Grant.

2013

  • ATVRE - Assistive Technologies for Virtual Rehabilitation Engineering; Feng D, Dehghani F, Dunstan C, Jin C, Kim J, Li Q, McEwan A, Ruys A, Brooker G, Buckley T, Cai T, Davis G, Fornusek C, Fulham M, Khadra M, Mohamed A, Murray G, Peck C, Vucetic B, Weiss A; DVC Research/Research Network Scheme (SyReNS).
  • Microstructural Design Strategies for Repairing Traumatic Skeletal Injuries; Zreiqat H, Dunstan C; Rebecca L Cooper Medical Research Foundation/Equipment Grant.
  • Novel Cytoplasmic Functions of the Vitamin D Receptor in Bone Metastases; Seibel M, Zheng Y, Croucher P, Zhou H, Guise T, Dunstan C; Cancer Council New South Wales/Research Project Grants.

2012

  • Pharmacological development of synthetic analogues of cytochrome P450-mediated omega-3 fatty acid epoxides as novel anti-metastatic agents; Murray M, Duke C, Cui P, Ching L, Dunstan C; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • The Instron testing material instrument (Model 5943); Dehghani F, Weiss A, Bilek M, Zreiqat H, Dunstan C, Chrzanowski W, Rohanizadeh R; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2010

  • Novel coatings for orthopaedic application; Zreiqat H, Sonnabend D, Dunstan C; Australian Orthopaedic Association Research Foundation Ltd/Research Support.
  • Harnessing the physiological effects of strontium and zinc to produce novel biomaterials for orthopaedic applications; Zreiqat H, Dunstan C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The Role of the Osteoblast in Mediating Glucocorticoid-induced Metabolic Dysfunction; Seibel M, Zhou H, Gundberg C, Dunstan C; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • Novel coatings for orthopaedic implants; Grau G, Little D, Zreiqat H, Dunstan C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Osteoblast Control of Mesenchymal Progenitor Cell Differentiation: The Role of Glucocorticoids and Wnt Signalling; Zhou H, Chen D, Seibel M, Chen D, Dunstan C; National Health and Medical Research Council (NHMRC)/Project Grants.

2008

  • Novel Scaffolds for repairing bone defects; Zreiqat H, Little D, Dunstan C; Australian Orthopaedic Association Research Foundation Ltd/Research Support.
  • FSH and Female Ageing; Allan C, Handelsman D, Dunstan C; National Health and Medical Research Council (NHMRC)/Project Grants.

2007

  • Illumina BeadXpress Reader for VeraCode Technology; Dunstan C; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Leica CM3050 S cryostat; Seibel M, Blair J, Dunstan C, Handelsman D, Nicholson G, Kennerson M, Lowe H, Witting P, Allan C, Zhou H; University of Sydney/Major Equipment.

2006

  • Glucocorticoid effects on bone: the role of the osteoblast; Seibel M, Zhou H, Dunstan C, Krozowski Z; National Health and Medical Research Council (NHMRC)/Project Grants.
  • KODAK Image Station 2000mm Multi-Modal Imager; Seibel M, Nicholson G, Witting P, Le Couteur D, Freedman B, Dunstan C, Blair J, Kennerson M, Myers S, Muller M; University of Sydney/Major Equipment.
  • Cell culture quarantine and storage facility plus assessories; Dunstan C, Witting P, Myers S, Handelsman D, Seibel M, Nicholson G, Zhou H, Kennerson M, Allan C, Freedman B, Le Couteur D, Muller M; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2005

  • Bone resorption in breast cancer metastasis; Blair J, Dunstan C, Seibel M, Zhou H; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Equipment Grant Glucocorticoids in inflammatory arthritis.; Dunstan C, Seibel M; Rebecca L Cooper/Medical Research Foundation.
  • Bio-Rad iCycler iQ5 Real-Time PCR & Mutation detection system; Seibel M, Le Couteur D, Freedman B, Nicholson G, Handelsman D, Kennerson M, Dunstan C, Allan C, Witting P, Kril J, Muller M; National Health and Medical Research Council (NHMRC)/Equipment Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Pivonka, P., Buenzli, P., Dunstan, C. (2012). A Systems Approach to Understanding Bone Cell Interactions in Health and Disease. In Sivakumar Gowder (Eds.), Cell Interaction, (pp. 169-204). Rijeka, Croatia: InTech Publishers.
  • Dunstan, C. (2009). How can periodontal bone loss be stopped? In Seymour, R; Henderson, B; Donas, N; Curtis, M. (Eds.), Periodontal Medicine and Systems Biology, (pp. 427-237). Chichester, UK: Wiley-Blackwell Publishing.
  • Dunstan, C., Blair, J., Zhou, H., Seibel, M. (2007). Bone, Mineral, Connective Tissue Metabolism. In Taylor J; Triggle D (vol ed Michael Williams) (Eds.), Comprehensive Medicinal Chemistry II, (pp. 495-520). Oxford, United Kingdom: Elsevier.
  • Dunstan, C. (2005). The role of RANK, RANK ligand and osteoprotegerin in the lytic effects and growth of bone metastases. In Claude Jasmin, Lawrence R. Coia, Rodolfo Capanna, Gerard Saillant (Eds.), Textbook of bone metastases, (pp. 51-62). United States: John Wiley & Sons.

Journals

  • Lu, Z., Wang, G., Roohani-Esfahani, S., Dunstan, C., Zreiqat, H. (2014). Baghdadite Ceramics Modulate the Cross Talk Between Human Adipose Stem Cells and Osteoblasts for Bone Regeneration. Tissue Engineering. Part A, 20(5-6), 992-1002. [More Information]
  • Zheng, Y., Chow, S., Boernert, K., Basel, D., Mikuscheva, A., Kim, S., Fong�?Yee, C., Trivedi, T., Buttgereit, F., Sutherland, R., Dunstan, C., Zhou, H., Seibel, M. (2014). Direct Cross-Talk Between Cancer and Osteoblast Lineage Cells Fuels Metastatic Growth in Bone via Auto-Amplification of IL-6 and RANKL Signaling Pathways. Journal of Bone and Mineral Research, 29(9), 1938-1949. [More Information]
  • Roohani-Esfahani, S., Wong, K., Lu, Z., Chen, Y., Li, J., Gronthos, S., Menicanin, D., Shi, J., Dunstan, C., Zreiqat, H. (2014). Fabrication of a novel triphasic and bioactive ceramic and evaluation of its in vitro and in vivo cytocompatibility and osteogenesis. Journal of Materials Chemistry B, 2(13), 1866-1878. [More Information]
  • Scheiner, S., Pivonka, P., Smith, D., Dunstan, C., Hellmich, C. (2014). Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab. International Journal for Numerical Methods in Biomedical Engineering, 30(1), 1-27. [More Information]
  • Lu, Z., Wang, G., Dunstan, C., Chen, Y., Lu, W., Davies, B., Zreiqat, H. (2013). Activation and Promotion of Adipose Stem Cells by Tumour Necrosis Factor-Alpha Preconditioning for Bone Regeneration. Journal of Cellular Physiology, 228(8), 1737-1744. [More Information]
  • Pivonka, P., Buenzli, P., Scheiner, S., Hellmich, C., Dunstan, C. (2013). The influence of bone surface availability in bone remodelling-A mathematical model including coupled geometrical and biomechanical regulations of bone cells. Engineering Structures, 47, 134-147. [More Information]
  • Zheng, Y., Zhou, H., Dunstan, C., Sutherland, R., Seibel, M. (2013). The role of the bone microenvironment in skeletal metastasis. Journal of Bone Oncology, 2(1), 47-57. [More Information]
  • Roohani-Esfahani, S., Dunstan, C., Li, J., Lu, Z., Davies, B., Pearce, S., Field, J., Williams, R., Zreiqat, H. (2013). Unique microstructural design of ceramic scaffolds for bone regeneration under load. Acta Biomaterialia, 9(6), 7014-7024. [More Information]
  • Smith, D., Gardiner, B., Dunstan, C. (2012). Bone Balance within a Cortical BMU: Local Controls of Bone Resorption and Formation. PloS One, 7(7), 1-12. [More Information]
  • Speranza, T., Henneicke, H., Gasparini, S., Blankenstein, K., Heinevetter, U., Cogger, V., Svistounov, D., Zhang, Y., Cooney, G., Buttgereit, F., Dunstan, C., Zhou, H., Seibel, M., et al (2012). Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. Journal of Clinical Investigation, 122(11), 4172-4189. [More Information]
  • Roohani-Esfahani, S., Dunstan, C., Davies, B., Pearce, S., Williams, R., Zreiqat, H. (2012). Repairing a critical-sized bone defect with highly porous modified and unmodified baghdadite scaffolds. Acta Biomaterialia, 8(11), 4162-4172. [More Information]
  • Pivonka, P., Dunstan, C. (2012). Role of mathematical modeling in bone fracture healing. BoneKEy Reports, Report 1 (2012), 221-1-221-10. [More Information]
  • Lu, Z., Wang, G., Dunstan, C., Zreiqat, H. (2012). Short-Term Exposure to Tumor Necrosis Factor-Alpha Enables Human Osteoblasts to Direct Adipose Tissue-Derived Mesenchymal Stem Cells into Osteogenic Differentiation. Stem Cells and Development, 21(13), 2420-2429. [More Information]
  • Kam, W., Meikle, S., Dunstan, C., Banati, R. (2012). The 18 kDa Translocator Protein (Peripheral Benzodiazepine Receptor) Expression in the Bone of Normal, Osteoprotegerin or Low Calcium Diet Treated Mice. PloS One, 7(1), 1-10. [More Information]
  • Stalgis-Bilinski, K., Boyages, J., Salisbury, E., Dunstan, C., Henderson, S., Talbot, P. (2011). Burning daylight: balancing vitamin D requirements with sensible sun exposure. Medical Journal of Australia, 194(7), 345-348. [More Information]
  • Wang, Y., Pivonka, P., Buenzli, P., Smith, D., Dunstan, C. (2011). Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment. PloS One, 6(11), e27494-1-e27494-21. [More Information]
  • Henneicke, H., Herrmann, M., Kalak, R., Speranza, T., Bertollo, N., Day, R., Huscher, D., Buttgereit, F., Dunstan, C., Seibel, M., Zhou, H. (2011). Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone, 49(4), 733-742. [More Information]
  • Fiford, R., Tomitsch, M., Dunstan, C., Plumbe, R. (2011). Exploring how elements of studio teaching can improve student engagement. Synergy, 31(July), 46-52.
  • Ooi, L., Zheng, Y., Stalgis-Bilinski, K., Dunstan, C. (2011). The bone remodeling environment is a factor in breast cancer bone metastasis. Bone, 48(1), 66-70. [More Information]
  • Goldhahn, J., Little, D., Mitchell, P., Fazzalari, N., Reid, I., Aspenberg, P., Marsh, D., Augat, P., Bavonratanavech, S., Bostrom, M., Dunstan, C., et al (2010). Evidence for anti-osteoporosis therapy in acute fracture situations-Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone, 46(2), 267-271. [More Information]
  • Allan, C., Kalak, R., Dunstan, C., McTavish, K., Zhou, H., Handelsman, D., Seibel, M. (2010). Follicle-stimulating hormone increases bone mass in female mice. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, Published online before print December 13, 2010, 1-6. [More Information]
  • Liu, P., Kalak, R., Lue, Y., Jia, Y., Erkkila, K., Zhou, H., Seibel, M., Wang, C., Swerdloff, R., Dunstan, C. (2010). Genetic and Hormonal Control of Bone Volume, Architecture, and Remodeling in XXY Mice. Journal of Bone and Mineral Research, 25(10), 2148-2154. [More Information]
  • Weber, A., Li, G., Kalak, R., Street, J., Buttgereit, F., Dunstan, C., Seibel, M., Zhou, H. (2010). Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. Steroids, 75(3), 282-286. [More Information]
  • Zreiqat, H., Ramaswamy, Y., Wu, C., Paschalidis, A., Lu, Z., James, B., Birke, O., McDonald, M., Little, D., Dunstan, C. (2010). The incorporation of strontium and zinc into a calcium-silicon ceramic for bone tissue engineering. Biomaterials, 31(12), 3175-3184. [More Information]
  • Ooi, L., Zheng, Y., Zhou, H., Trivedi, T., Conigrave, A., Seibel, M., Dunstan, C. (2010). Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone, 47(4), 795-803. [More Information]
  • Ooi, L., Zhou, H., Kalak, R., Zheng, Y., Conigrave, A., Seibel, M., Dunstan, C. (2010). Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Research, 70(5), 1835-1844. [More Information]
  • Zheng, Y., Zhou, H., Ooi, L., Snir, A., Dunstan, C., Seibel, M. (2010). Vitamin D deficiency promotes prostate cancer growth in bone. The Prostate, , 1-10. [More Information]
  • Mak, W., Shao, X., Dunstan, C., Seibel, M., Zhou, H. (2009). Biphasic Glucocorticoid-Dependent Regulation of Wnt Expression and Its Inhibitors in Mature Osteoblastic Cells. Calcified Tissue International, 85(6), 538-545. [More Information]
  • Wang, C., Karlis, G., Anderson, G., Dunstan, C., Carbone, A., Berger, G., Ploska, U., Zreiqat, H. (2009). Bone growth is enhanced by novel bioceramic coatings on Ti alloy implants. Journal of Biomedical Materials Research. Part A, 90A(2), 419-428. [More Information]
  • Dunstan, C., Ooi, L. (2009). CXCL12/CXCR4 Axis in Tissue Targeting and Bone Destruction in Cancer and Multiple Myeloma. Journal of Bone and Mineral Research, 24(7), 1147-1149.
  • Kalak, R., Zhou, H., Street, J., Day, R., Modzelewski, J., Spies, C., Liu, P., Li, G., Dunstan, C., Seibel, M. (2009). Endogenous glucocorticoid signaling in osteoblasts is necessary to maintain normal bone structure in mice. Bone, 45(1), 61-67. [More Information]
  • Zhou, H., Mak, W., Kalak, R., Street, J., Fong-Yee, C., Zheng, Y., Dunstan, C., Seibel, M. (2009). Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development (Cambridge), 136(3), 427-436. [More Information]
  • Blair, J., Modzelewski, J., Perryman, L., Russell, P., Seibel, M., Dunstan, C. (2009). Prolonged Antiresorptive Treatment of Lytic Prostate Cancer Xenografts in Mouse Bone Results in Tumor Necrosis. Journal of Cancer Molecules, 4(6), 175-181.
  • Ramaswamy, Y., Wu, C., Dunstan, C., Hewson, B., Eindorf, T., Anderson, G., Zreiqat, H. (2009). Sphene ceramics for orthopedic coating applications: An in vitro and in vivo study. Acta Biomaterialia, 5(8), 3192-3204. [More Information]
  • Herrmann, M., Henneicke, H., Street, J., Modzelewski, J., Kalak, R., Buttgereit, F., Dunstan, C., Zhou, H., Seibel, M. (2009). The challenge of continuous exogenous glucocorticoid administration in mice. Steroids, 74(2), 245-249. [More Information]
  • Pivonka, P., Zimak, J., Smith, D., Gardiner, B., Dunstan, C., Sims, N., Martin, T., Mundy, G. (2009). Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology, 262(2), 306-316.
  • Buttgereit, F., Zhou, H., Kalak, R., Gaber, T., Spies, C., Huscher, D., Straub, R., Modzelewski, J., Dunstan, C., Seibel, M. (2009). Transgenic Disruption of Glucocorticoid Signaling in Mature Osteoblasts and Osteocytes Attenuates K/BxN Mouse Serum-Induced Arthritis In Vivo. Arthritis Care and Research, 60(7), 1998-2007. [More Information]
  • Zheng, Y., Zhou, H., Fong-Yee, C., Modzelewski, J., Seibel, M., Dunstan, C. (2008). Bone Resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clinical and Experimental Metastasis, 25(5), 559-567. [More Information]
  • Pivonka, P., Zimak, J., Smith, D., Gardiner, B., Dunstan, C., Sims, N., Martin, T., Mundy, G. (2008). Model structure and control of bone remodeling: A theoretical study. Bone, 43, 249-263. [More Information]
  • Zhou, H., Mak, W., Zheng, Y., Dunstan, C., Seibel, M. (2008). Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through WNT signaling. Journal of Biological Chemistry, 283(4), 1936-1945. [More Information]
  • Zheng, Y., Zhou, H., Modzelewski, J., Kalak, R., Blair, J., Seibel, M., Dunstan, C. (2007). Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Research, 67(19), 9542-9548. [More Information]
  • Dunstan, C., Felsenberg, D., Seibel, M. (2007). Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature Clinical Practice Oncology, 4(1), 42-45. [More Information]
  • Zheng, Y., Brennan, K., Blair, J., Modzelewski, J., Seibel, M., Dunstan, C. (2006). Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone, 40(2), 471-478. [More Information]
  • Blair, J., Zhou, H., Seibel, M., Dunstan, C. (2006). Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Clinical Practice Oncology, 3(1), 41-49. [More Information]
  • Blair, J., Zheng, Y., Dunstan, C. (2006). RANK ligand. The International Journal of Biochemistry and Cell Biology, 39(6), 1077-1081. [More Information]
  • Meier, C., Meinhardt, U., Greenfield, J., Modzelewski, J., Nguyen, T., Dunstan, C., Seibel, M. (2006). Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clinical Laboratory, 52(1-2), 1-10. [More Information]
  • Seibel, M., Dunstan, C., Zhou, H., Allan, C., Handelsman, D. (2006). Sex steroids, not FSH, influence bone mass. Cell, 127(6), 1079-1079. [More Information]
  • Geusens, P., Landewé, R., Garnero, P., Chen, D., Dunstan, C., Lems, W., Stinissen, P., van der Heijde, D., van der Linden, S., Boers, M. (2006). The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis and Rheumatism, 54(6), 1772-1777. [More Information]
  • Padagas, J., Colloton, M., Shalhoub, V., Kostenuik, P., Morony, S., Munyakazi, L., Guo, M., Gianneschi, D., Shatzen, E., Dunstan, C., et al (2006). The receptor activator of nuclear factor-kappa B ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcified Tissue International, 78(1), 35-44.
  • Valenta, A., Roschger, P., Fratzl-Zelman, N., Kostenuik, P., Dunstan, C., Fratzl, P., Klaushofer, K. (2005). Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone, 37(1), 87-95. [More Information]
  • Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H., Capparelli, C., Starnes, C., Dunstan, C., et al (2005). The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology, 146(8), 3235-3243. [More Information]
  • Bekker, P., Holloway, D., Rasmussen, A., Murphy, R., Martin, S., Leese, P., Holmes, G., Dunstan, C., DePaoli, A. (2004). A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research, 19(7), 1059-1066.
  • Theoleyre, S., Wittrant, Y., Couillaud, S., Vusio, P., Berreur, M., Dunstan, C., Blanchard, F., Rédini, F., Heymann, D. (2004). Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kB ligand and MAPK. BBA: Biochimica et Biophysica Acta - Molecular Cell Research, 1644 (1), 1-7. [More Information]
  • Dunstan, C., Zhou, H., Seibel, M. (2004). Fibroblast Growth Factor 23: A Phospatonin Regulating Phosphate Homeostasis? Endocrinology, 145(7), 3084-3086.
  • Wittrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., Redini, F. (2004). Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Experimental Cell Research: emphasizing molecular approaches to cell biology, 293(2), 292-301.
  • Zwerina, J., Hayer, S., Tohidast-Akrad, M., Bergmeister, H., Redlich, K., Feige, U., Dunstan, C., Kollias, G., Steiner, G., Smolen, J., et al (2004). Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Care and Research, 50(1), 277-290.
  • Kiefer, J., Vessella, R., Quinn, J., Odman, A., Zhang, J., Keller, E., Kostenuik, P., Dunstan, C., Corey, E. (2004). The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical and Experimental Metastasis, 21(5), 381-387. [More Information]
  • Body, J., Greipp, P., Coleman, R., Facon, T., Geurs, F., Fermand, J., Harousseau, J., Lipton, A., Mariette, X., Williams, C., Dunstan, C., et al (2003). A Phase 1 Study of AMGN-0007, a Recombinant Osteoprotegerin Construct, in Patients with Multiple Myeloma or Breast Cancer-Related Bone Metastases. Cancer, 97(3), 887-892.
  • Smith, B., Cosenza, M., Mancini, A., Dunstan, C., Gregson, R., Martin, S., Smith, S., Davis, H. (2003). A toxicity profile of osteoprotegerin in the cynomolgus monkey. International Journal of Toxicology, 22, 403-412.
  • Doherty, T., Asotra, K., Fitzpatrick, L., Qiao, J., Wilkin, D., Detrano, R., Dunstan, C., Shah, P., Rajavashisth, T. (2003). Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 100(20), 11201-11206.
  • Ashcroft, A., Cruickshank, S., Croucher, P., Perry, M., Rollinson, S., Lippitt, J., Child, J., Dunstan, C., Felsburg, P., Morgan, G., et al (2003). Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity, 19, 849-861.
  • Riggs, B., Khosla, S., Atkinson, E., Dunstan, C., Melton, L. (2003). Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporosis International, 14, 728-733. [More Information]
  • Fohr, B., Dunstan, C., Seibel, M. (2003). Markers of bone remodeling in metastatic bone disease. Journal of Clinical Endocrinology and Metabolism, 88(11), 5059-5075.
  • Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Gortz, B., Schulz, A., Bergmeister, H., Kollias, G., et al (2003). Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Care and Research, 48(7), 2042-2051. [More Information]
  • Wittrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., Redini, F. (2003). Regulation of osteoclast protease expression by RANKL. Biochemical and Biophysical Research Communications, 310, 774-778. [More Information]
  • Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C., Stouch, B., Martin, S., Kostenuik, P. (2003). Sustained anti-resorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. Journal of Bone and Mineral Research, 18(5), 852-858.
  • Khosla, S., Arrighi, H., Melton, L., Atkinson, E., O'Fallon, W., Dunstan, C., Riggs, B. (2002). Correlates of osteoprotegerin levels in women and men. Osteoporosis International, 13(5), 394-399.
  • Khosla, S., Atkinson, E., Dunstan, C., O'Fallon, W. (2002). Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism, 87(4), 1550-1554.
  • Wittrant, Y., Couillaud, S., Theoleyre, S., Dunstan, C., Heymann, D., Redini, F. (2002). Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochemical & Biophysical Research Communications. Biochemical and Biophysical Research Communications, 293, 38-44.
  • Romas, E., Sims, N., Hards, D., Lindsay, M., Quinn, J., Ryan, P., Dunstan, C., Martin, T., Gillespie, M. (2002). Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis. The American Journal of Pathology: cellular and molecular biology of disease, 161(4), 1419-1427.
  • Doherty, T., Uzui, H., Fitzpatrick, L., Tripathi, P., Dunstan, C., Asotra, K., Rajavashisth, T. (2002). Rationale for the role of osteoclast-like cells in arterial calcification. The F A S E B Journal, 16, 577-582.
  • Lipton, A., Ali, S., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Holloway, D., Bekker, P., Dunstan, C. (2002). Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research, 8, 2306-2310.
  • Redlich, K., Hayer, S., Maier, A., Dunstan, C., Tohidast-Akrad, M., Lang, S., Turk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al (2002). Tumor Necrosis Factor alpha - Mediated Joint Destruction Is Inhibited by Targeting Osteoclasts With Osteoprotegerin. Arthritis Care and Research, 46(3), 785-792.

Conferences

  • Buenzli, P., Pivonka, P., Gardiner, B., Smith, D., Dunstan, C., Mundy, G. (2010). Theoretical analysis of the spatio-temporal structure of bone multicellular units. 9th World Congress on Computational Mechanics and 4th Asian Pacific Congress on Computational Mechanics WCCM-APCOM 2010, Sydney: IOP Publishing. [More Information]
  • Liu, P., Kalak, R., Lue, Y., Erkkilla, K., Simanainen, U., Zhou, H., Hikim, A., Handelsman, D., Seibel, M., Wang, C., Dunstan, C., et al (2007). XXY Mice have an Osteoporotic Phenotype. 29th Annual Meeting American Society for Bone and Mineral Research (ASBMR), Washington DC, USA: American Society for Bone and Mineral Research.
  • Seibel, M., Blair, J., Perryman, L., Pwint, H., Lelliott, J., De Winter, J., Russell, P., Dunstan, C. (2005). Osteoprotegerin treatment inhibits the growth of lytic prostate cancer lesions in bone. 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, New York: Elsevier Science.
  • Meier, C., Meinhardt, U., Greenfield, J., Dunstan, C., Seibel, M. (2005). Serum cathepsin K levels reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget''s disease. 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, New York: Elsevier Science.

Magazine / Newspaper Articles

  • Lu, W., McKenzie, D., Dunstan, C., Zreiqat, H., Bilek, M. (2012). Plasma Immersion Ion Implantation Treatment of Poly-ether Ether Ketone for the Immobilization of Biomolecules on Surfaces (ID: 836). International Forum of Biomedical Materials: Nanobiomaterials for Tissue Regeneration.

Reference Works

  • Zhou, H., Chen, D., Dunstan, C., Seibel, M. (2009). Bone Metabolism. In Stefan Offermanns, Walter Rosenthal (Eds.), Bone Metabolism. (Vol. 1, pp. 276-282). USA: Springer.

2014

  • Lu, Z., Wang, G., Roohani-Esfahani, S., Dunstan, C., Zreiqat, H. (2014). Baghdadite Ceramics Modulate the Cross Talk Between Human Adipose Stem Cells and Osteoblasts for Bone Regeneration. Tissue Engineering. Part A, 20(5-6), 992-1002. [More Information]
  • Zheng, Y., Chow, S., Boernert, K., Basel, D., Mikuscheva, A., Kim, S., Fong�?Yee, C., Trivedi, T., Buttgereit, F., Sutherland, R., Dunstan, C., Zhou, H., Seibel, M. (2014). Direct Cross-Talk Between Cancer and Osteoblast Lineage Cells Fuels Metastatic Growth in Bone via Auto-Amplification of IL-6 and RANKL Signaling Pathways. Journal of Bone and Mineral Research, 29(9), 1938-1949. [More Information]
  • Roohani-Esfahani, S., Wong, K., Lu, Z., Chen, Y., Li, J., Gronthos, S., Menicanin, D., Shi, J., Dunstan, C., Zreiqat, H. (2014). Fabrication of a novel triphasic and bioactive ceramic and evaluation of its in vitro and in vivo cytocompatibility and osteogenesis. Journal of Materials Chemistry B, 2(13), 1866-1878. [More Information]
  • Scheiner, S., Pivonka, P., Smith, D., Dunstan, C., Hellmich, C. (2014). Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab. International Journal for Numerical Methods in Biomedical Engineering, 30(1), 1-27. [More Information]

2013

  • Lu, Z., Wang, G., Dunstan, C., Chen, Y., Lu, W., Davies, B., Zreiqat, H. (2013). Activation and Promotion of Adipose Stem Cells by Tumour Necrosis Factor-Alpha Preconditioning for Bone Regeneration. Journal of Cellular Physiology, 228(8), 1737-1744. [More Information]
  • Pivonka, P., Buenzli, P., Scheiner, S., Hellmich, C., Dunstan, C. (2013). The influence of bone surface availability in bone remodelling-A mathematical model including coupled geometrical and biomechanical regulations of bone cells. Engineering Structures, 47, 134-147. [More Information]
  • Zheng, Y., Zhou, H., Dunstan, C., Sutherland, R., Seibel, M. (2013). The role of the bone microenvironment in skeletal metastasis. Journal of Bone Oncology, 2(1), 47-57. [More Information]
  • Roohani-Esfahani, S., Dunstan, C., Li, J., Lu, Z., Davies, B., Pearce, S., Field, J., Williams, R., Zreiqat, H. (2013). Unique microstructural design of ceramic scaffolds for bone regeneration under load. Acta Biomaterialia, 9(6), 7014-7024. [More Information]

2012

  • Pivonka, P., Buenzli, P., Dunstan, C. (2012). A Systems Approach to Understanding Bone Cell Interactions in Health and Disease. In Sivakumar Gowder (Eds.), Cell Interaction, (pp. 169-204). Rijeka, Croatia: InTech Publishers.
  • Smith, D., Gardiner, B., Dunstan, C. (2012). Bone Balance within a Cortical BMU: Local Controls of Bone Resorption and Formation. PloS One, 7(7), 1-12. [More Information]
  • Speranza, T., Henneicke, H., Gasparini, S., Blankenstein, K., Heinevetter, U., Cogger, V., Svistounov, D., Zhang, Y., Cooney, G., Buttgereit, F., Dunstan, C., Zhou, H., Seibel, M., et al (2012). Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. Journal of Clinical Investigation, 122(11), 4172-4189. [More Information]
  • Lu, W., McKenzie, D., Dunstan, C., Zreiqat, H., Bilek, M. (2012). Plasma Immersion Ion Implantation Treatment of Poly-ether Ether Ketone for the Immobilization of Biomolecules on Surfaces (ID: 836). International Forum of Biomedical Materials: Nanobiomaterials for Tissue Regeneration.
  • Roohani-Esfahani, S., Dunstan, C., Davies, B., Pearce, S., Williams, R., Zreiqat, H. (2012). Repairing a critical-sized bone defect with highly porous modified and unmodified baghdadite scaffolds. Acta Biomaterialia, 8(11), 4162-4172. [More Information]
  • Pivonka, P., Dunstan, C. (2012). Role of mathematical modeling in bone fracture healing. BoneKEy Reports, Report 1 (2012), 221-1-221-10. [More Information]
  • Lu, Z., Wang, G., Dunstan, C., Zreiqat, H. (2012). Short-Term Exposure to Tumor Necrosis Factor-Alpha Enables Human Osteoblasts to Direct Adipose Tissue-Derived Mesenchymal Stem Cells into Osteogenic Differentiation. Stem Cells and Development, 21(13), 2420-2429. [More Information]
  • Kam, W., Meikle, S., Dunstan, C., Banati, R. (2012). The 18 kDa Translocator Protein (Peripheral Benzodiazepine Receptor) Expression in the Bone of Normal, Osteoprotegerin or Low Calcium Diet Treated Mice. PloS One, 7(1), 1-10. [More Information]

2011

  • Stalgis-Bilinski, K., Boyages, J., Salisbury, E., Dunstan, C., Henderson, S., Talbot, P. (2011). Burning daylight: balancing vitamin D requirements with sensible sun exposure. Medical Journal of Australia, 194(7), 345-348. [More Information]
  • Wang, Y., Pivonka, P., Buenzli, P., Smith, D., Dunstan, C. (2011). Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment. PloS One, 6(11), e27494-1-e27494-21. [More Information]
  • Henneicke, H., Herrmann, M., Kalak, R., Speranza, T., Bertollo, N., Day, R., Huscher, D., Buttgereit, F., Dunstan, C., Seibel, M., Zhou, H. (2011). Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone, 49(4), 733-742. [More Information]
  • Fiford, R., Tomitsch, M., Dunstan, C., Plumbe, R. (2011). Exploring how elements of studio teaching can improve student engagement. Synergy, 31(July), 46-52.
  • Ooi, L., Zheng, Y., Stalgis-Bilinski, K., Dunstan, C. (2011). The bone remodeling environment is a factor in breast cancer bone metastasis. Bone, 48(1), 66-70. [More Information]

2010

  • Goldhahn, J., Little, D., Mitchell, P., Fazzalari, N., Reid, I., Aspenberg, P., Marsh, D., Augat, P., Bavonratanavech, S., Bostrom, M., Dunstan, C., et al (2010). Evidence for anti-osteoporosis therapy in acute fracture situations-Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone, 46(2), 267-271. [More Information]
  • Allan, C., Kalak, R., Dunstan, C., McTavish, K., Zhou, H., Handelsman, D., Seibel, M. (2010). Follicle-stimulating hormone increases bone mass in female mice. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, Published online before print December 13, 2010, 1-6. [More Information]
  • Liu, P., Kalak, R., Lue, Y., Jia, Y., Erkkila, K., Zhou, H., Seibel, M., Wang, C., Swerdloff, R., Dunstan, C. (2010). Genetic and Hormonal Control of Bone Volume, Architecture, and Remodeling in XXY Mice. Journal of Bone and Mineral Research, 25(10), 2148-2154. [More Information]
  • Weber, A., Li, G., Kalak, R., Street, J., Buttgereit, F., Dunstan, C., Seibel, M., Zhou, H. (2010). Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. Steroids, 75(3), 282-286. [More Information]
  • Zreiqat, H., Ramaswamy, Y., Wu, C., Paschalidis, A., Lu, Z., James, B., Birke, O., McDonald, M., Little, D., Dunstan, C. (2010). The incorporation of strontium and zinc into a calcium-silicon ceramic for bone tissue engineering. Biomaterials, 31(12), 3175-3184. [More Information]
  • Buenzli, P., Pivonka, P., Gardiner, B., Smith, D., Dunstan, C., Mundy, G. (2010). Theoretical analysis of the spatio-temporal structure of bone multicellular units. 9th World Congress on Computational Mechanics and 4th Asian Pacific Congress on Computational Mechanics WCCM-APCOM 2010, Sydney: IOP Publishing. [More Information]
  • Ooi, L., Zheng, Y., Zhou, H., Trivedi, T., Conigrave, A., Seibel, M., Dunstan, C. (2010). Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone, 47(4), 795-803. [More Information]
  • Ooi, L., Zhou, H., Kalak, R., Zheng, Y., Conigrave, A., Seibel, M., Dunstan, C. (2010). Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Research, 70(5), 1835-1844. [More Information]
  • Zheng, Y., Zhou, H., Ooi, L., Snir, A., Dunstan, C., Seibel, M. (2010). Vitamin D deficiency promotes prostate cancer growth in bone. The Prostate, , 1-10. [More Information]

2009

  • Mak, W., Shao, X., Dunstan, C., Seibel, M., Zhou, H. (2009). Biphasic Glucocorticoid-Dependent Regulation of Wnt Expression and Its Inhibitors in Mature Osteoblastic Cells. Calcified Tissue International, 85(6), 538-545. [More Information]
  • Wang, C., Karlis, G., Anderson, G., Dunstan, C., Carbone, A., Berger, G., Ploska, U., Zreiqat, H. (2009). Bone growth is enhanced by novel bioceramic coatings on Ti alloy implants. Journal of Biomedical Materials Research. Part A, 90A(2), 419-428. [More Information]
  • Zhou, H., Chen, D., Dunstan, C., Seibel, M. (2009). Bone Metabolism. In Stefan Offermanns, Walter Rosenthal (Eds.), Bone Metabolism. (Vol. 1, pp. 276-282). USA: Springer.
  • Dunstan, C., Ooi, L. (2009). CXCL12/CXCR4 Axis in Tissue Targeting and Bone Destruction in Cancer and Multiple Myeloma. Journal of Bone and Mineral Research, 24(7), 1147-1149.
  • Kalak, R., Zhou, H., Street, J., Day, R., Modzelewski, J., Spies, C., Liu, P., Li, G., Dunstan, C., Seibel, M. (2009). Endogenous glucocorticoid signaling in osteoblasts is necessary to maintain normal bone structure in mice. Bone, 45(1), 61-67. [More Information]
  • Zhou, H., Mak, W., Kalak, R., Street, J., Fong-Yee, C., Zheng, Y., Dunstan, C., Seibel, M. (2009). Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development (Cambridge), 136(3), 427-436. [More Information]
  • Dunstan, C. (2009). How can periodontal bone loss be stopped? In Seymour, R; Henderson, B; Donas, N; Curtis, M. (Eds.), Periodontal Medicine and Systems Biology, (pp. 427-237). Chichester, UK: Wiley-Blackwell Publishing.
  • Blair, J., Modzelewski, J., Perryman, L., Russell, P., Seibel, M., Dunstan, C. (2009). Prolonged Antiresorptive Treatment of Lytic Prostate Cancer Xenografts in Mouse Bone Results in Tumor Necrosis. Journal of Cancer Molecules, 4(6), 175-181.
  • Ramaswamy, Y., Wu, C., Dunstan, C., Hewson, B., Eindorf, T., Anderson, G., Zreiqat, H. (2009). Sphene ceramics for orthopedic coating applications: An in vitro and in vivo study. Acta Biomaterialia, 5(8), 3192-3204. [More Information]
  • Herrmann, M., Henneicke, H., Street, J., Modzelewski, J., Kalak, R., Buttgereit, F., Dunstan, C., Zhou, H., Seibel, M. (2009). The challenge of continuous exogenous glucocorticoid administration in mice. Steroids, 74(2), 245-249. [More Information]
  • Pivonka, P., Zimak, J., Smith, D., Gardiner, B., Dunstan, C., Sims, N., Martin, T., Mundy, G. (2009). Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology, 262(2), 306-316.
  • Buttgereit, F., Zhou, H., Kalak, R., Gaber, T., Spies, C., Huscher, D., Straub, R., Modzelewski, J., Dunstan, C., Seibel, M. (2009). Transgenic Disruption of Glucocorticoid Signaling in Mature Osteoblasts and Osteocytes Attenuates K/BxN Mouse Serum-Induced Arthritis In Vivo. Arthritis Care and Research, 60(7), 1998-2007. [More Information]

2008

  • Zheng, Y., Zhou, H., Fong-Yee, C., Modzelewski, J., Seibel, M., Dunstan, C. (2008). Bone Resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clinical and Experimental Metastasis, 25(5), 559-567. [More Information]
  • Pivonka, P., Zimak, J., Smith, D., Gardiner, B., Dunstan, C., Sims, N., Martin, T., Mundy, G. (2008). Model structure and control of bone remodeling: A theoretical study. Bone, 43, 249-263. [More Information]
  • Zhou, H., Mak, W., Zheng, Y., Dunstan, C., Seibel, M. (2008). Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through WNT signaling. Journal of Biological Chemistry, 283(4), 1936-1945. [More Information]

2007

  • Zheng, Y., Zhou, H., Modzelewski, J., Kalak, R., Blair, J., Seibel, M., Dunstan, C. (2007). Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Research, 67(19), 9542-9548. [More Information]
  • Dunstan, C., Blair, J., Zhou, H., Seibel, M. (2007). Bone, Mineral, Connective Tissue Metabolism. In Taylor J; Triggle D (vol ed Michael Williams) (Eds.), Comprehensive Medicinal Chemistry II, (pp. 495-520). Oxford, United Kingdom: Elsevier.
  • Dunstan, C., Felsenberg, D., Seibel, M. (2007). Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature Clinical Practice Oncology, 4(1), 42-45. [More Information]
  • Liu, P., Kalak, R., Lue, Y., Erkkilla, K., Simanainen, U., Zhou, H., Hikim, A., Handelsman, D., Seibel, M., Wang, C., Dunstan, C., et al (2007). XXY Mice have an Osteoporotic Phenotype. 29th Annual Meeting American Society for Bone and Mineral Research (ASBMR), Washington DC, USA: American Society for Bone and Mineral Research.

2006

  • Zheng, Y., Brennan, K., Blair, J., Modzelewski, J., Seibel, M., Dunstan, C. (2006). Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone, 40(2), 471-478. [More Information]
  • Blair, J., Zhou, H., Seibel, M., Dunstan, C. (2006). Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Clinical Practice Oncology, 3(1), 41-49. [More Information]
  • Blair, J., Zheng, Y., Dunstan, C. (2006). RANK ligand. The International Journal of Biochemistry and Cell Biology, 39(6), 1077-1081. [More Information]
  • Meier, C., Meinhardt, U., Greenfield, J., Modzelewski, J., Nguyen, T., Dunstan, C., Seibel, M. (2006). Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clinical Laboratory, 52(1-2), 1-10. [More Information]
  • Seibel, M., Dunstan, C., Zhou, H., Allan, C., Handelsman, D. (2006). Sex steroids, not FSH, influence bone mass. Cell, 127(6), 1079-1079. [More Information]
  • Geusens, P., Landewé, R., Garnero, P., Chen, D., Dunstan, C., Lems, W., Stinissen, P., van der Heijde, D., van der Linden, S., Boers, M. (2006). The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis and Rheumatism, 54(6), 1772-1777. [More Information]
  • Padagas, J., Colloton, M., Shalhoub, V., Kostenuik, P., Morony, S., Munyakazi, L., Guo, M., Gianneschi, D., Shatzen, E., Dunstan, C., et al (2006). The receptor activator of nuclear factor-kappa B ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcified Tissue International, 78(1), 35-44.

2005

  • Valenta, A., Roschger, P., Fratzl-Zelman, N., Kostenuik, P., Dunstan, C., Fratzl, P., Klaushofer, K. (2005). Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone, 37(1), 87-95. [More Information]
  • Seibel, M., Blair, J., Perryman, L., Pwint, H., Lelliott, J., De Winter, J., Russell, P., Dunstan, C. (2005). Osteoprotegerin treatment inhibits the growth of lytic prostate cancer lesions in bone. 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, New York: Elsevier Science.
  • Meier, C., Meinhardt, U., Greenfield, J., Dunstan, C., Seibel, M. (2005). Serum cathepsin K levels reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget''s disease. 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, New York: Elsevier Science.
  • Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H., Capparelli, C., Starnes, C., Dunstan, C., et al (2005). The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology, 146(8), 3235-3243. [More Information]
  • Dunstan, C. (2005). The role of RANK, RANK ligand and osteoprotegerin in the lytic effects and growth of bone metastases. In Claude Jasmin, Lawrence R. Coia, Rodolfo Capanna, Gerard Saillant (Eds.), Textbook of bone metastases, (pp. 51-62). United States: John Wiley & Sons.

2004

  • Bekker, P., Holloway, D., Rasmussen, A., Murphy, R., Martin, S., Leese, P., Holmes, G., Dunstan, C., DePaoli, A. (2004). A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research, 19(7), 1059-1066.
  • Theoleyre, S., Wittrant, Y., Couillaud, S., Vusio, P., Berreur, M., Dunstan, C., Blanchard, F., Rédini, F., Heymann, D. (2004). Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kB ligand and MAPK. BBA: Biochimica et Biophysica Acta - Molecular Cell Research, 1644 (1), 1-7. [More Information]
  • Dunstan, C., Zhou, H., Seibel, M. (2004). Fibroblast Growth Factor 23: A Phospatonin Regulating Phosphate Homeostasis? Endocrinology, 145(7), 3084-3086.
  • Wittrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., Redini, F. (2004). Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Experimental Cell Research: emphasizing molecular approaches to cell biology, 293(2), 292-301.
  • Zwerina, J., Hayer, S., Tohidast-Akrad, M., Bergmeister, H., Redlich, K., Feige, U., Dunstan, C., Kollias, G., Steiner, G., Smolen, J., et al (2004). Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Care and Research, 50(1), 277-290.
  • Kiefer, J., Vessella, R., Quinn, J., Odman, A., Zhang, J., Keller, E., Kostenuik, P., Dunstan, C., Corey, E. (2004). The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical and Experimental Metastasis, 21(5), 381-387. [More Information]

2003

  • Body, J., Greipp, P., Coleman, R., Facon, T., Geurs, F., Fermand, J., Harousseau, J., Lipton, A., Mariette, X., Williams, C., Dunstan, C., et al (2003). A Phase 1 Study of AMGN-0007, a Recombinant Osteoprotegerin Construct, in Patients with Multiple Myeloma or Breast Cancer-Related Bone Metastases. Cancer, 97(3), 887-892.
  • Smith, B., Cosenza, M., Mancini, A., Dunstan, C., Gregson, R., Martin, S., Smith, S., Davis, H. (2003). A toxicity profile of osteoprotegerin in the cynomolgus monkey. International Journal of Toxicology, 22, 403-412.
  • Doherty, T., Asotra, K., Fitzpatrick, L., Qiao, J., Wilkin, D., Detrano, R., Dunstan, C., Shah, P., Rajavashisth, T. (2003). Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 100(20), 11201-11206.
  • Ashcroft, A., Cruickshank, S., Croucher, P., Perry, M., Rollinson, S., Lippitt, J., Child, J., Dunstan, C., Felsburg, P., Morgan, G., et al (2003). Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity, 19, 849-861.
  • Riggs, B., Khosla, S., Atkinson, E., Dunstan, C., Melton, L. (2003). Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporosis International, 14, 728-733. [More Information]
  • Fohr, B., Dunstan, C., Seibel, M. (2003). Markers of bone remodeling in metastatic bone disease. Journal of Clinical Endocrinology and Metabolism, 88(11), 5059-5075.
  • Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Gortz, B., Schulz, A., Bergmeister, H., Kollias, G., et al (2003). Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Care and Research, 48(7), 2042-2051. [More Information]
  • Wittrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., Redini, F. (2003). Regulation of osteoclast protease expression by RANKL. Biochemical and Biophysical Research Communications, 310, 774-778. [More Information]
  • Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C., Stouch, B., Martin, S., Kostenuik, P. (2003). Sustained anti-resorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. Journal of Bone and Mineral Research, 18(5), 852-858.

2002

  • Khosla, S., Arrighi, H., Melton, L., Atkinson, E., O'Fallon, W., Dunstan, C., Riggs, B. (2002). Correlates of osteoprotegerin levels in women and men. Osteoporosis International, 13(5), 394-399.
  • Khosla, S., Atkinson, E., Dunstan, C., O'Fallon, W. (2002). Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism, 87(4), 1550-1554.
  • Wittrant, Y., Couillaud, S., Theoleyre, S., Dunstan, C., Heymann, D., Redini, F. (2002). Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochemical & Biophysical Research Communications. Biochemical and Biophysical Research Communications, 293, 38-44.
  • Romas, E., Sims, N., Hards, D., Lindsay, M., Quinn, J., Ryan, P., Dunstan, C., Martin, T., Gillespie, M. (2002). Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis. The American Journal of Pathology: cellular and molecular biology of disease, 161(4), 1419-1427.
  • Doherty, T., Uzui, H., Fitzpatrick, L., Tripathi, P., Dunstan, C., Asotra, K., Rajavashisth, T. (2002). Rationale for the role of osteoclast-like cells in arterial calcification. The F A S E B Journal, 16, 577-582.
  • Lipton, A., Ali, S., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Holloway, D., Bekker, P., Dunstan, C. (2002). Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research, 8, 2306-2310.
  • Redlich, K., Hayer, S., Maier, A., Dunstan, C., Tohidast-Akrad, M., Lang, S., Turk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al (2002). Tumor Necrosis Factor alpha - Mediated Joint Destruction Is Inhibited by Targeting Osteoclasts With Osteoprotegerin. Arthritis Care and Research, 46(3), 785-792.

To update your profile click here. For support on your academic profile contact .